Peter Mac researchers have discovered a powerful new drug combination that could offer hope to children and adults with ...

Two years ago, Grafton learned he had stage 4 lung cancer. But thanks to a clinical trial at Duke funded by the National ...

AbbVie ABBV has been expanding its oncology portfolio over the past few years. While the company was originally focused on two blood-cancer drugs — Imbruvica and Venclexta — it has since built a ...

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

Merck MRK announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The deal will add ...

Dizal Pharmaceutical’s Zegfrovy is now FDA approved for treating non-small cell lung cancer driven by a particular rare genetic signature. Johnson & Johnson drug Rybrevant already addresses this ...

(Reuters) -AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing ...

Screening for disease, including cancer, can cause harm —during screening, diagnosis and treatment. With lung cancer screening, a positive scan can prompt an invasive lung biopsy.

We reviewed the evidence assessing the relationship between vitamins or antioxidant intake and lung cancer prevention, mortality and adverse events for that cancer. This review updates our Cochrane ...

New data indicate a targeted drug from Nuvalent could help patients with a rare lung cancer for whom other drugs stopped working ...

Amgen Inc. (NASDAQ:AMGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 2, Amgen announced new interim results from the global Phase 3 DeLLphi-304 trial for its drug IMDELLTRA ...